Di Yi Cai Jing·2025-05-07 08:58Group 1 - In Q1 2025, sales of semaglutide surpassed Merck's Keytruda by $664 million, marking semaglutide as the temporary global "king of drugs" [1][2] - Novo Nordisk reported Q1 2025 global sales of semaglutide at 55.776 billion Danish kroner (approximately $7.864 billion), a year-on-year increase of 32.17%, accounting for about 71% of the company's total revenue [1][3] - Merck's Keytruda reported Q1 2025 global sales of $7.2 billion, with a year-on-year growth of 4%, indicating a slowdown compared to its 18% growth in 2024 [2][3] Group 2 - Semaglutide's growth is driven by its indications for weight loss, with Ozempic sales at 32.721 billion Danish kroner (approximately $4.613 billion, up 15%), Rybelsus at 5.695 billion Danish kroner (approximately $0.803 billion, up 13%), and Wegovy at 17.36 billion Danish kroner (approximately $2.448 billion, up 83%) [3] - Novo Nordisk highlighted that approximately 1 billion people suffer from obesity, but only a few million receive treatment, indicating a significant market opportunity for Wegovy [3] - Competition is intensifying with Eli Lilly's dual agonist tirzepatide, which has cumulative sales of $6.15 billion, although semaglutide's sales still lead [3][4] Group 3 - Eli Lilly holds a 53.3% market share in the U.S. for GLP-1 receptor agonists, indicating strong competition in the market [4] - Novo Nordisk has revised its full-year 2025 sales growth forecast from 16%-24% to 13%-21%, and its operating profit forecast from 19%-27% to 16%-24%, primarily due to lower-than-expected market penetration of semaglutide in the U.S. [4]